We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-2.06%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$302M
AUM Growth
-$211M
Cap. Flow
-$176M
Cap. Flow %
-58.3%
Top 10 Hldgs %
99.8%
Holding
11
New
–
Increased
–
Reduced
4
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$127M
2
ALGS icon
Aligos Therapeutics
ALGS
+$24.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$21.3M
4
FLXN
Flexion Therapeutics, Inc.
FLXN
+$2.64M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.64B
$82.3M 27.28%
508,558
-1,046,402
-67% -$127M
PASG icon
2
Passage Bio
PASG
$14.2M
$65.7M 21.76%
247,988
– –
ALGS icon
3
Aligos Therapeutics
ALGS
$25.9M
$47.3M 15.67%
92,815
-38,879
-30% -$24.8M
GRTS
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$40.6M 13.46%
4,450,638
– –
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$17.7M 5.88%
506,823
– –
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.88B
$15.5M 5.13%
820,720
-1,209,896
-60% -$21.3M
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$15.3M 5.08%
617,727
– –
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.23M 2.73%
1,000,000
-310,169
-24% -$2.64M
APRE icon
9
Aprea Therapeutics
APRE
$7.43M
$6.15M 2.04%
62,983
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$2.37M 0.79%
543,753
– –
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$591K 0.2%
101,855
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2021 Portfolio in Review

As of Q2 2021, Versant Venture Management held 11 positions worth $302M, down 41% from $513M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $176M in Q2 2021, reducing 4 holdings. Its largest reduction was CRISPR Therapeutics, cutting an estimated $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's biggest Q2 2021 reduction was CRISPR Therapeutics, cutting an estimated $127M.
  • Versant Venture Management's ten largest holdings make up 100% of its $302M portfolio in Q2 2021.
  • Versant Venture Management opened 0 new positions and closed 0 in Q2 2021.
  • Versant Venture Management's portfolio value fell 41% quarter-over-quarter to $302M.

Based on Versant Venture Management's 13F filing for Q2 2021, filed 12 Aug 2021.